<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-07-24">July 24, 2017.</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD, Charit</roleName><forename type="first">Marcus</forename><surname>Maurer</surname></persName>
							<email>marcus.maurer@charite.de</email>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Martin</forename><surname>Metz</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Randolf</forename><surname>Brehler</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Derma-tology and Allergology</orgName>
								<orgName type="department" key="dep2">University Medical Center Gießen (UKGM)</orgName>
								<orgName type="institution" key="instit1">Klinik f€ ur Hautkrankheiten</orgName>
								<orgName type="institution" key="instit2">Universit€ atsklinikum M€ unster; c Klinik f€ ur Dermatologie und Venerologie</orgName>
								<address>
									<addrLine>Vivantes-Klinikum Berlin-Neuk€ olln</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">Justus Liebig University Gießen</orgName>
								<address>
									<settlement>Giessen</settlement>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution" key="instit1">Friedrich-Alexander-University Erlangen-Nuremberg</orgName>
								<orgName type="institution" key="instit2">Saarland Univer-sity Medical School</orgName>
								<address>
									<settlement>Homburg</settlement>
									<country>Saar</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Uwe</forename><surname>Hillen</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Thilo</forename><surname>Jakob</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Vera</forename><surname>Mahler</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Claudia</forename><surname>Pf€ Ohler</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Petra</forename><surname>Staubach</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Hautklinik und Poliklinik</orgName>
								<orgName type="department" key="dep2">Department of Dermatology, Venereology and Allergology</orgName>
								<orgName type="institution" key="instit1">Universit€ atsmedi-zin Mainz</orgName>
								<orgName type="institution" key="instit2">Leipzig Interdisciplinary Allergy Center (LICA)</orgName>
								<orgName type="institution" key="instit3">University Medical Center</orgName>
								<address>
									<settlement>Leipzig</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Regina</forename><surname>Treudler</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, i</roleName><forename type="first">Bettina</forename><surname>Wedi</surname></persName>
						</author>
						<author>
							<persName><roleName>MD a Berlin</roleName><forename type="first">Markus</forename><surname>Magerl</surname></persName>
						</author>
						<author>
							<persName><forename type="first">I</forename><surname>Klinik F€ Ur Dermatologie</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Allergologie</forename><surname>Und Venerologie</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Medizinische</forename><surname>Hoch- Schule</surname></persName>
						</author>
						<author>
							<persName><surname>-Universit€ Atsmedizin Berlin</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution">Erlangen-Nuremberg</orgName>
								<address>
									<settlement>Homburg/Saar, Mainz, Leipzig, Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<address>
									<settlement>Charit e-Universit€ atsmedizin Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="institution">Paul-Ehrlich-Institut</orgName>
								<address>
									<settlement>Langen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<address>
									<addrLine>Charit eplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-07-24">July 24, 2017.</date>
						</imprint>
					</monogr>
					<idno type="MD5">3B3FAFB7DB0505457357E49A69B2733B</idno>
					<idno type="DOI">10.1016/j.jaci.2017.06.032</idno>
					<note type="submission">Received for publication April 6, 2017; revised June 9, 2017; accepted for publication June 30, 2017.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:23+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>IgE</term>
					<term>physical urticaria</term>
					<term>therapy</term>
					<term>symptomatic dermographism</term>
					<term>cholinergic urticaria</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Omalizumab, a recombinant anti-IgE antibody, effectively treats chronic spontaneous urticaria.</s><s>Evidence is lacking in patients with chronic inducible urticarias (CIndUs), which are frequently H 1 -antihistamine resistant.</s><s>Objective: From the current published literature, we aimed to determine the strength of evidence for omalizumab efficacy and safety in the treatment of CIndUs.</s></p><p><s>Methods: We performed a PubMed search to identify evidence on omalizumab use in the following 9 CIndU subtypes: symptomatic dermographism, cold urticaria, delayed-pressure urticaria, solar urticaria, heat urticaria, vibratory angioedema, cholinergic urticaria, contact urticaria, and aquagenic urticaria.</s><s>Results: Forty-three trials, case studies, case reports, and analyses were identified.</s><s>Our review indicates that omalizumab has substantial benefits in patients with various CIndUs.</s><s>The evidence is strongest for symptomatic dermographism, cold urticaria, and solar urticaria.</s><s>Little/no evidence was available on vibratory angioedema and aquagenic and contact urticaria.</s><s>Our review supports rapid onset of action demonstrated through early symptom control in most cases, sometimes within 24 hours.</s><s>Many patients gained complete/partial symptom relief and substantially improved quality of life.</s><s>Adverse events were generally low, with omalizumab being well tolerated by most patients, including children.</s><s>Conclusions: A strong body of evidence supports the use of omalizumab in the treatment of patients with therapy-refractory CIndU.</s><s>More data from randomized controlled studies are warranted.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abbreviations used</head><p><s>AE: Adverse event CIndU: Chronic inducible urticaria CSU: Chronic spontaneous urticaria CU: Chronic urticaria DLQI: Dermatology Life Quality Index QoL: Quality of life However, many patients do not, <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b3">4</ref> in which case third-line treatments, including omalizumab, are recommended. <ref type="bibr" target="#b0">1</ref></s><s>Omalizumab, a recombinant humanized anti-IgE antibody, is now approved as add-on therapy in patients with H 1 -antihistaminerefractory CSU, and thus from clinical experience, it might be expected that patients with CIndUs could also benefit. <ref type="bibr" target="#b8">9</ref></s><s>malizumab has been used to successfully treat CSU, with strong evidence coming from randomized controlled trials, <ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref> real-life studies, <ref type="bibr" target="#b16">17</ref> and a meta-analysis. <ref type="bibr" target="#b17">18</ref></s><s>However, omalizumab is not licensed for CIndUs, and large-scale trials are lacking.</s><s>The first reported case of omalizumab use in a patient with a CIndU was by Boyce <ref type="bibr" target="#b18">19</ref> in 2006, and since that time, a body of evidence has accumulated in the form of trials, case studies, reports, and retrospective analyses.</s><s>1]<ref type="bibr" target="#b21">[22]</ref> Guideline recommendations for CSU are frequently adopted in the absence of good-quality evidence for CIndUs.</s></p><p><s>In the current systematic review we have aimed to determine, from the current published literature, existing evidence for the efficacy and safety of omalizumab in the treatment of CIndUs.</s><s>Some rare atypical forms of CIndUs exist (ie, cholinergic dermographism), but this review focuses on the 9 major subtypes (Table <ref type="table" target="#tab_0">I</ref>).</s></p><p><s>4]<ref type="bibr" target="#b24">[25]</ref> As of now, it is unclear exactly what causes this activation and degranulation.</s><s>Type I autoimmunity, sometimes also referred to as autoallergy, has been postulated to be a cause of CIndU. <ref type="bibr" target="#b25">26</ref></s><s>In patients with autoimmune type I urticaria, skin mast cells are activated by an IgEmediated reaction to autoantigen.</s><s>7]<ref type="bibr" target="#b27">[28]</ref> Many patients with CSU exhibit IgE autoantibodies directed against thyroid peroxidase (IgE-anti-thyroid peroxidase), and these patients have higher levels of total IgE and IgG-anti-thyroid peroxidase and lymphocyte counts in their serum/blood. <ref type="bibr" target="#b28">29</ref></s><s>1]<ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref> Relevant autoantigens detected by using IgE have been identified and characterized in part, such as in solar urticaria. <ref type="bibr" target="#b33">34</ref></s><s>Desensitization, which works in patients with cold urticaria and other CindUs, has been shown not to work through depletion of mast cells or mast cell mediators, but rather, it is suggested to work through depletion of the mast cell-activating signal. <ref type="bibr" target="#b26">27</ref></s><s>in mast cell degranulation in patients with solar urticaria, for example, occurs when skin is exposed to UV radiation.</s><s>Mast cell degranulation is thought to involve IgE that is specific for photo-induced neoantigens that act as autoallergens.</s><s>This IgE is bound to FcεRI, the high-affinity IgE receptor on cutaneous mast cells, which is activated by neoantigen-mediated cross-linking of IgE and the receptor.</s><s>Because omalizumab blocks binding of IgE to FcεRI, <ref type="bibr" target="#b34">35</ref> it can intervene in this pathway, and mast cell activation and the inflammatory process are suppressed subsequently.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head><p><s>We performed a MEDLINE search (pubmed.com) to identify evidence of the use of omalizumab in each CIndU subtype, with no restrictions on time period covered or publication language.</s><s>The advanced search option was used with the terms ''omalizumab'' AND, for example, ''cold urticaria'' to encompass results from all fields.</s><s>This was complemented by any additional published or in press evidence known to us at the time of publication (Table <ref type="table" target="#tab_1">II</ref>). <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b19">20,</ref> All </s><s>blications have been included, regardless of whether the results were positive or negative, to present a fair and unbiased account of the available published evidence.</s><s>Review articles have been excluded.</s><s>Publications have been split into 2 groups based on the number of patients included in the report: case series or studies with 5 or more patients and case reports or small case series of fewer than 5 patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p><s>We found overlap of CIndU subtypes between studies, and although many of the case studies presented include several patients, the numbers shown in Table <ref type="table" target="#tab_1">II</ref> relate only to the number of patients within the specified subtype.</s></p><p><s>A total of 43 trials, case studies, case reports, and retrospective analyses on the use of omalizumab in patients with CIndUs were identified and included in this review (Fig <ref type="figure" target="#fig_1">2</ref>).</s><s>Overall, 3 phase II studies were identified in patients with solar urticaria, <ref type="bibr" target="#b35">36</ref> cold urticaria, <ref type="bibr" target="#b36">37</ref> and symptomatic dermographism, <ref type="bibr" target="#b37">38</ref> of which the latter 2 were randomized and placebo controlled.</s><s>Most published evidence comes from single case reports, small case studies, or larger case studies that also include some patients with CSU.</s></p><p><s>Overall, the vast majority of results indicate a beneficial role for omalizumab in each type of CIndU, but evidence for certain subtypes was stronger than for others, as described under each heading below.</s><s>To our knowledge, all doses of omalizumab were administered subcutaneously, as per the instructions.</s><s>Adverse events (AEs) were generally found to be low, with omalizumab being well tolerated by most patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Physical urticarias</head><p><s>Symptomatic dermographism.</s><s>Symptomatic dermographism is the most common type of physical urticaria, <ref type="bibr" target="#b76">77</ref> with a prevalence of up to 5% in the general population. <ref type="bibr" target="#b77">78</ref></s><s>It involves whealing and pruritus after minor stroking, rubbing, or scratching of the skin, which can be unavoidable in daily life and can therefore substantially impair QoL. <ref type="bibr" target="#b78">79,</ref><ref type="bibr" target="#b79">80</ref></s><s>Antihistamines can be used to effectively treat the majority of patients, but in some cases, further treatment is required.</s></p><p><s>We identified 7 publications on omalizumab use in patients with symptomatic dermographism encompassing a total of 72 patients (including 54 omalizumab-and 18 placebo-treated patients).</s><s>The strongest evidence came from a randomized, placebo-controlled trial involving 55 patients with symptomatic dermographism, who had a high mean baseline Dermatology Life Quality Index (DLQI) score of 11.1, indicating a very high effect on QoL. <ref type="bibr" target="#b37">38</ref></s><s>Results showed significant improvement in critical friction thresholds (the strongest trigger strength to induce symptoms) after 10 weeks of treatment with 150 mg (21.8 6 0.4, P 5 .014)</s><s>and 300 mg (22.0 6 0.4, P 5 .004) of omalizumab versus placebo-treated patients (20.6 6 0.3), with improvements observed as early as week 4.</s><s>No significant difference in efficacy was observed between the 2 omalizumab doses, and efficacy was not affected by variations in baseline trigger thresholds or disease activity.</s><s>After 10 weeks of treatment, 6 (33%) of 18 receiving 150 mg of omalizumab and 8 (42%) of 19 patients receiving 300 mg of omalizumab did not respond at all compared with 15 (83%) of 18 placebo-treated patients. <ref type="bibr" target="#b37">38</ref></s><s> retrospective analysis showed 86% of patients achieved a complete response (absence of wheals after provocation testing/ absence of symptoms assessed by Patient Global Assessment) and 14% had a significant improvement (&gt; _50% reduction in provocation thresholds/&gt; _50% improvement of symptoms).</s><s><ref type="bibr" target="#b38">39</ref> Another analysis showed that 1 of 2 patients achieved complete/almost complete response to treatment, <ref type="bibr" target="#b39">40</ref> and 2 further analyses by Metz et al <ref type="bibr" target="#b40">41,</ref><ref type="bibr" target="#b41">42</ref> showed slightly differing results.</s><s>In the first, one patient who received 300 mg of omalizumab achieved complete symptom control, but another patient, who began treatment with 150 mg and then updosed to 300 mg, did not.</s><s><ref type="bibr" target="#b40">41</ref> Both patients had previously tried 9 different medications to control their CIndU with little success.</s><s>In the second analysis all 4 patients (1 with symptomatic dermographism plus CSU) gained complete symptom control, with no need for additional medication after the first treatment.</s><s><ref type="bibr" target="#b41">42</ref> Finally, 2 case reports showed further positive results.</s><s>In the first report a patient with antihistamine-refractory symptomatic dermographism who was treated with 300 mg of omalizumab every 2 weeks gained major reductions in pruritus and whealing within the first week, with complete symptom relief by the fourth week.</s><s><ref type="bibr" target="#b42">43</ref> In the other report a patient with coexisting symptomatic dermographism, delayed-pressure urticaria, and CSU achieved complete remission within 24 hours of receiving 150 mg of omalizumab.</s><s><ref type="bibr" target="#b43">44</ref> Cold urticaria. Co</s><s>d urticaria is the second most prevalent physical urticaria. <ref type="bibr" target="#b76">77</ref> Wheal</s><s>, angioedema, or both develop within minutes of touching something cold, and there is a serious risk of anaphylaxis or oropharyngeal edema.</s><s><ref type="bibr" target="#b44">45,</ref><ref type="bibr" target="#b80">[81]</ref><ref type="bibr" target="#b81">[82]</ref><ref type="bibr" target="#b83">[83]</ref><ref type="bibr" target="#b85">[84]</ref> Robust evidence exists for cold urticaria, totaling 63 reported cases of omalizumab use (including 51 omalizumab-and 12 placebo-treated patients) across 11 publications.</s><s>The first reported use was in 2006 in a 12-year-old patient with a 2-year history of cold urticaria and asthma.</s><s><ref type="bibr" target="#b18">19</ref> The patient was given 375 mg of omalizumab every 2 weeks and, after the second injection, could tolerate cold liquids with only mild pruritus.</s><s>After 5 months, symptoms had completely disappeared, and ice cube test responses were negative.</s><s><ref type="bibr" target="#b41">42,</ref><ref type="bibr" target="#b44">45</ref> More recently, results from a randomized, placebo-controlled trial including 31 patients with cold urticaria demonstrated significant clinical superiority of omalizumab versus placebo.</s><s><ref type="bibr" target="#b36">37</ref> Because cold urticaria can be life-threatening, and very limited/ no efficacy was seen with placebo treatment, the study was terminated after interim result analysis.</s><s>Mean changes in critical temperature thresholds (required to induce symptoms) after 10 weeks were significantly higher in patients receiving 150 mg (210.68C</s><s>6 2.48C, P 5 .001)</s><s>and 300 mg (210.48C</s><s>6 3.18C, P 5 .013) of omalizumab compared with placebo (20.38C 6 1.18C).</s><s>Improvements were seen by week 4. No</s><s>ignificant difference in efficacy was observed between the 2 doses, and variations in baseline critical temperature thresholds did not affect efficacy.</s><s>After 10 weeks of treatment, 1 (10%) of 10 patients receiving 150 mg of omalizumab and 2 (22%) of 9 patients receiving 300 mg of omalizumab were nonresponders compared with 9 (75%) of 12 placebo-treated patients.</s></p><p><s>Some case series also demonstrate substantial benefits; Kitsioulis et al <ref type="bibr" target="#b45">46</ref> reported significant QoL improvements in 5 children with cold urticaria (children's DLQI scores decreased by 41.46% [13.4% to 65.3%, SD 5 18.66%]) after 5 months of treatment, whereas an improvement was observed after the first month (decrease range, 17.65% to 40%; SD 5 10.35) in 80% of these patients.</s><s>Another set of cases showed that 6 patients all became symptom free after treatment, with a significant decrease in cold stimulation tolerance tests. <ref type="bibr" target="#b46">47</ref></s><s>ne case report showed significant improvements after an initial omalizumab injection and complete control after the second injection, <ref type="bibr" target="#b47">48</ref> whereas another described a 2-year-old patient with severe systemic reactions on exposure to cold conditions whose symptoms dramatically improved after treatment with 75 mg of omalizumab every 4 weeks. <ref type="bibr" target="#b48">49</ref></s><s>However, 2 more reports suggest that only around half of patients included in an analyses responded well to omalizumab, <ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b39">40</ref> and one case described a patient in which 300 mg of omalizumab treatment every 4 weeks did not adequately control symptoms, with treatment discontinued after 8 months because of repeated fatigue and somnolence. <ref type="bibr" target="#b44">45</ref></s><s>elayed-pressure urticaria.</s><s>Delayed-pressure urticaria frequently coexists with CSU but is rare as a primary inducible urticaria. <ref type="bibr" target="#b13">14</ref></s><s>Because of its nature, the condition frequently goes unrecognized and can be difficult to attribute to a single trigger because symptoms typically occur 4 to 6 hours after, for example, wearing tight clothing, walking, or sitting. <ref type="bibr" target="#b86">85</ref></s><s>Lesions are painful and persist for up to 3 days.</s><s>This subtype has been reported to cause significantly greater QoL impairment than other forms of urticaria <ref type="bibr" target="#b87">86</ref> and is normally unresponsive to high doses of antihistamines or corticosteroids. <ref type="bibr" target="#b49">50</ref></s><s>e identified 11 publications of omalizumab including 26 patients with delayed-pressure urticaria.</s><s>The first reported use of omalizumab was by Bindslev-Jensen and Skov 51 in a patient with a 10-year history whose previous medications (540 mg/d fexofenadine and 100 mg/d azathioprine) provided only partial relief, the benefits of which were gradually diminishing.</s><s>Once 150 mg of omalizumab was started (given concomitantly with fexofenadine), total symptom relief was achieved after 2 days.</s><s>This was followed quickly by more case reports describing complete responders after just 1 injection. <ref type="bibr" target="#b40">41,</ref><ref type="bibr" target="#b51">52,</ref><ref type="bibr" target="#b52">53</ref></s><s>In another case involving a patient with coexisting delayed-pressure urticaria, symptomatic dermographism, and CSU, complete remission was seen within 24 hours of 150 mg of omalizumab treatment, <ref type="bibr" target="#b43">44</ref> and 3 other cases reported the same result in which a 300-mg dose achieved complete symptom control within 2 days <ref type="bibr" target="#b53">54,</ref><ref type="bibr" target="#b54">55</ref> and another within 5 days. <ref type="bibr" target="#b49">50</ref></s><s>owever, some reports showed mixed results: 2 patients with concurrent CSU and delayed-pressure urticaria showed a complete remission after the first injection of omalizumab. <ref type="bibr" target="#b55">56</ref></s><s>In a third patient with severe delayed-pressure urticaria and CSU who had received ineffectual treatment for more than 20 years, omalizumab reduced the symptoms of CSU but intensified those of delayed-pressure urticaria, and the drug was withdrawn after 2 cycles.</s><s>In the largest analysis including 8 patients, 7 (88%) achieved complete symptom control, whereas 1 (12%) had significant improvements after treatment, <ref type="bibr" target="#b38">39</ref> and another showed 3 (60%) of 5 patients with a complete response. <ref type="bibr" target="#b39">40</ref></s><s>olar urticaria.</s><s>Solar urticaria is a rare form of CIndU. <ref type="bibr" target="#b88">87</ref></s><s>It is characterized by skin lesions at sites of photo-exposed skin, usually within minutes of UV radiation, including long-wavelength UVA, short-wavelength UVB, and/or visible light. <ref type="bibr" target="#b89">88</ref></s><s>It seriously affects QoL, and there is a risk of anaphylaxis should the entire body be exposed. <ref type="bibr" target="#b88">87,</ref><ref type="bibr" target="#b90">89</ref></s><s>f all CIndU subtypes, solar urticaria had the highest number of publications on omalizumab use.</s><s>Of 18 publications that included 36 cases, the majority showed that omalizumab successfully controlled symptoms, whereas 4 included patients with a partial response, <ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b41">42,</ref><ref type="bibr" target="#b56">57,</ref><ref type="bibr" target="#b57">58</ref> and 3 showed failure to respond to treatment. <ref type="bibr" target="#b39">40,</ref><ref type="bibr" target="#b58">59,</ref><ref type="bibr" target="#b59">60</ref></s><s>he strongest evidence came from a multicenter, prospective, phase II study including 10 antihistamine-refractory patients with solar urticaria that greatly affected their QoL (DLQI score of &gt;10). <ref type="bibr" target="#b35">36</ref></s><s>After 3 doses of omalizumab over an 8-week period, 20% of patients met the primary end point (95% CI, 2.52-55.6;</s><s>P 5 .2639),</s><s>whereby symptoms were not triggered by a UV dose of greater than 10-fold the baseline minimal urticarial dose at week 12.</s><s>Additionally, 40% of patients achieved a DLQI score of less than 6, and 40% achieved an improvement in severity (measured on a visual analogue scale) of 50%.</s><s>No significant AEs were experienced during the study.</s></p><p><s>2]<ref type="bibr" target="#b62">[63]</ref><ref type="bibr" target="#b63">[64]</ref><ref type="bibr" target="#b64">[65]</ref><ref type="bibr" target="#b65">[66]</ref><ref type="bibr" target="#b66">[67]</ref> Initial doses in these cases ranged from 150 to 375 mg, although in some patients a higher dose of 450 mg was necessary to achieve complete symptom control. <ref type="bibr" target="#b61">62,</ref><ref type="bibr" target="#b67">68</ref></s><s>Patients often relapsed 2 to 8 weeks after discontinuing treatment but then responded well to the next omalizumab injection. <ref type="bibr" target="#b41">42</ref></s><s>One case of omalizumab use in a 6-year-old child was reported after approval from an ethics committee for exceptional medical treatments. <ref type="bibr" target="#b68">69</ref></s><s>An initial dose of 75 mg did not achieve any apparent improvement, and therefore the dose was gradually increased to 300 mg twice monthly, after which complete remission was gained with no side effects.</s></p><p><s>In the case of treatment failure, 1 patient received 4 doses of 150 mg of omalizumab every 4 weeks with no clinical improvement and no changes in phototests, although the authors speculate that a higher dose and longer treatment could have been more effective. <ref type="bibr" target="#b58">59</ref></s><s>There was one report of worsening symptoms after 3 doses of 150 mg of omalizumab, indicating that this treatment is not suitable in all patients. <ref type="bibr" target="#b59">60</ref></s><s>eat urticaria.</s><s>Heat urticaria is triggered by various forms of heat, such as air, water, or objects.</s><s>It is an uncommon physical urticaria and difficult to manage effectively. <ref type="bibr" target="#b91">90</ref></s><s>Avoiding all forms of heat poses a great challenge in everyday life and is often not feasible.</s></p><p><s>Evidence of omalizumab use in patients with heat urticaria is limited and comes from just 4 publications covering 5 case reports.</s><s>Two patients seriously affected by their condition whose symptoms were insufficiently controlled by conventional treatments achieved marked clinical improvements after the first doses of 300 mg of omalizumab. <ref type="bibr" target="#b69">70</ref></s><s>In one of these cases, the heat application test response became negative.</s></p><p><s>In another case report, almost complete symptom control was achieved after a patient received 4 doses of omalizumab, alternating between 300 mg and 450 mg biweekly. <ref type="bibr" target="#b19">20</ref></s><s>The    450-mg dose achieved greater symptom improvement compared with the 300-mg dose, and the patient received a total of 38 doses with no side effects and no need for concomitant medication.</s><s>Two other case reports described less favorable responses with either no significant improvement <ref type="bibr" target="#b38">39</ref> or only minor improvements in 1 patient with an extremely treatment-resistant form of heat urticaria, as indicated by 9 prior medications, including loratadine, cetirizine, and montelukast. <ref type="bibr" target="#b40">41</ref></s><s>ibratory angioedema.</s><s>Vibratory angioedema, a very rare form of CIndU, is characterized by eruption of pruriginous erythema within minutes of vibratory contact to the skin. <ref type="bibr" target="#b3">4</ref></s><s>It is induced typically by vibratory motions, such as running or using an electric lawnmower or pneumatic drill.</s><s>Only one case report of omalizumab use in vibratory angioedema was found, which did not improve symptoms. <ref type="bibr" target="#b70">71</ref></s><s>her inducible urticarias Cholinergic urticaria.</s><s>Cholinergic urticaria is characterized by pin-sized wheals with surrounding erythema and extreme pruritus.</s><s>Symptoms are induced by increases in core body temperature through, for example, physical exercise or emotional stress.</s><s>In most cases, symptoms are mild to moderate, but sometimes wheals cover the entire body, and antihistamines are often ineffectual. <ref type="bibr" target="#b92">91</ref></s><s>ne case series involving 8 patients 39 and 6 smaller case reports/series <ref type="bibr" target="#b39">40,</ref><ref type="bibr" target="#b41">42,</ref><ref type="bibr" target="#b71">[72]</ref><ref type="bibr" target="#b72">[73]</ref><ref type="bibr" target="#b73">[74]</ref><ref type="bibr" target="#b74">[75]</ref> were identified for omalizumab use in patients with cholinergic urticaria, totaling 20 reported cases.</s><s>The retrospective analysis by Metz et al <ref type="bibr" target="#b38">39</ref> showed that 62% of patients achieved a complete response (absence of wheals after provocation testing/absence of symptoms assessed by Patient Global Assessment), 13% had a significant improvement (&gt; _50% reduction in provocation thresholds/&gt; _50% improvement of symptoms), and 25% showed no significant improvement (&lt;50% reduction in provocation thresholds/improvement of symptoms).</s><s>Most patients started on 150 mg of omalizumab, with 1 patient receiving 300 mg.</s><s>Another analysis showed greater benefits: 3 patients with cholinergic urticaria and 1 with cholinergic urticaria plus cold urticaria achieved complete symptom control with no need for any concomitant medication. <ref type="bibr" target="#b41">42</ref></s><s>Disease relapsed within 2 to 8 weeks of omalizumab discontinuation, despite patients taking antihistamines.</s><s>In another study 75% of patients achieved complete responses with omalizumab therapy. <ref type="bibr" target="#b39">40</ref></s><s>Three case studies indicated great improvement of symptoms: 2 cases describe patients' symptoms drastically improving after only 1 dose of omalizumab, as measured by the DLQI score and the Chronic Urticaria Quality of Life Questionnaire, respectively. <ref type="bibr" target="#b72">73,</ref><ref type="bibr" target="#b74">75</ref></s><s>In addition, 1 patient had also had severe dyspeptic complaints, which almost completely disappeared. <ref type="bibr" target="#b74">75</ref></s><s>n another case a patient significantly improved after the second injection of 300 mg of omalizumab, and concomitant medication was reduced. <ref type="bibr" target="#b71">72</ref></s><s>ne case is reported of a patient whose symptoms were unresponsive to 300 mg of omalizumab treatment given every 2 weeks, although the author speculates that lack of response might be related to high IgE levels, and a higher dose might have produced more successful results. <ref type="bibr" target="#b73">74</ref></s><s>ontact urticaria.</s><s>Contact urticaria is characterized by wheals and angioedema that occur in response to contact with urticariaogenic substances.</s><s>Mast cell activation is either nonimmunologic (ie, without prior sensitization to the eliciting agent) or immunologic (ie, IgE mediated). <ref type="bibr" target="#b93">92</ref></s><s>We did not identify any reported uses of omalizumab in patients with contact urticaria.</s></p><p><s>Aquagenic urticaria.</s><s>Aquagenic urticaria is a rare inducible CIndU that occurs when the skin is exposed to water, including sweat and tears.</s><s>Patients typically present with 1-to 3-mm wheals with surrounding 1-to 3-cm erythematous flares within minutes of water contact. <ref type="bibr" target="#b91">90</ref></s><s>In some cases symptoms can be more severe and include wheezing or shortness of breath.</s><s>The nature of this subtype has an obvious effect on QoL because simple activities, such as bathing, can become almost impossible.</s><s>Many patients are refractory to H 1 -antihistamines and require further interventions.</s></p><p><s>Only one case of omalizumab treatment in a patient with aquagenic urticaria was identified. <ref type="bibr" target="#b75">76</ref></s><s>A patient with a 2-year history of aquagenic urticaria whose condition was uncontrolled by previous medications, including montelukast, cetirizine, loratadine, ranitidine, diphenhydramine, and hydroxyzine, was started on 300 mg of omalizumab per month.</s><s>Symptoms completely resolved after 2 omalizumab doses, and the patients was able to go swimming for the first time in many years and discontinued other medications without symptom recurrence.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AEs</head><p><s>Overall, instances of AEs were low and rarely led to treatment discontinuation.</s><s>In one study involving a mixture of patients with CSU and those with CIndUs, 14% of patients overall reported AEs during treatment, including suspected allergic reactions, gastrointestinal symptoms, injection-site reactions, worsening urticaria, headache, dizziness, arthritis, and fatigue. <ref type="bibr" target="#b39">40</ref></s><s>In another analysis of 51 patients (again including both patients with CSU and those with CIndU), no unwanted side effects were reported from omalizumab, except one case in which treatment was discontinued after mild cutaneous angioedema several hours after administration. <ref type="bibr" target="#b38">39</ref></s><s>In the 2 placebo-controlled randomized trials in patients with cold urticaria and symptomatic dermographism, the frequency of AEs was similar between the omalizumab and placebo groups. <ref type="bibr" target="#b36">37</ref></s><s>ne patient with cold urticaria discontinued treatment because of inadequate symptom control and AEs, including fatigue and somnolence. <ref type="bibr" target="#b44">45</ref></s><s>n investigator-initiated urticaria registry has been set up to prospectively monitor patients with CU (http://www.urticariaregistry.com).</s><s>This has now almost reached its 1000th patient and will provide valuable future data on the efficacy and AEs of treatments of CIndU patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>A large body of evidence has accumulated for omalizumab use in patients with CIndUs since the first reported use in 2006. <ref type="bibr" target="#b18">19</ref></s><s>Two randomized controlled trials, several sizable case series, and many case reports exist to indicate that omalizumab provides substantial benefits in patients with various CIndUs, but more data on efficacy and safety from controlled (licensing) studies are needed.</s></p><p><s>The dose of omalizumab used appears to be important based on individual patient needs; because of the nature of this review, which includes all published evidence (excluding review articles), a range of different doses was used across the studies.</s><s>Some studies showed no apparent difference between omalizumab doses, <ref type="bibr" target="#b36">37,</ref><ref type="bibr" target="#b37">38</ref> whereas in many studies a lower dose of 150 mg was sufficient to elicit a good response, <ref type="bibr" target="#b36">37,</ref><ref type="bibr" target="#b37">38,</ref><ref type="bibr" target="#b43">44,</ref><ref type="bibr" target="#b50">51</ref> and in others higher doses generally appeared to be more efficacious, which is supported by previous evidence. <ref type="bibr" target="#b17">18</ref></s><s>Depending on the type of CIndU and the age and weight of the patient, doses should be tailored to individual patients' needs.</s><s>In some of the reported treatment failures, it was speculated that a higher dose could have produced more success, and in some cases the benefits of updosing to reach maximal effects were apparent. <ref type="bibr" target="#b61">62,</ref><ref type="bibr" target="#b67">68</ref></s><s>ifferences between omalizumab treatment in patients with CIndU versus patients with CSU were discovered, with the dose required to gain a response being the major difference between the 2 populations.</s><s>1]<ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref> The effective dose in patients with CSU appears to plateau at around 300 mg, with 75 mg having failed to show a meaningful response, and doses of greater than 300 mg generally not showing greater efficacy in omalizumab-naive patients.</s><s>However, this differed in responses to omalizumab in patients with CIndUs.</s><s>The 2 randomized trials in symptomatic dermographism <ref type="bibr" target="#b37">38</ref> and cold urticaria <ref type="bibr" target="#b36">37</ref> both tested 150 and 300 mg in the relevant patients, but no significant differences between the doses were observed at any time during the study, indicating that the lower dose of 150 mg might be more appropriate in this patient population.</s><s>This requires further investigation, including studies that confirm earlier results showing that omalizumab updosing is effective in patients with CIndU (and patients with CSU) who do not respond to their initial dose of omalizumab. <ref type="bibr" target="#b38">39</ref></s><s>ne common theme identified was that many patients had already tried several medications in an attempt to control their urticaria symptoms, and for some, most treatment options had been exhausted.</s><s>Considering this, omalizumab provided at least partial, if not complete, relief for the majority of these patients after several years of discomfort.</s></p><p><s>Published clinical trials demonstrate that response to omalizumab in patients with CSU is evident within the first weeks of treatment, <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b12">13</ref> and our review also supports the rapid onset of action in patients with CIndUs, as demonstrated through early symptom control recorded in most publications.</s><s>However, the question of time to response is important, and not all patients respond to treatment in the same manner and at the same speed.</s><s>Time to response has been shown to differ between patients, and future characterization of predictive factors might lead to better prognosis and treatment of distinct patient groups. <ref type="bibr" target="#b94">93</ref></s><s>A recent study in patients with CSU has shown that the majority of patients respond within the first 8 days, with around one third responding on day 1 <ref type="bibr" target="#b94">93</ref> and around 12% not responding.</s><s>Similar studies are needed for patients with CIndUs.</s></p><p><s>One publication was identified in which patients received more than 1 course of omalizumab treatment. <ref type="bibr" target="#b41">42</ref></s><s>A total of 16 patients with 5 different CIndUs (some with coexisting CSU) were treated with omalizumab doses of between 150 and 600 mg/mo, and disease activity was determined by trigger threshold testing or by the patient's history.</s><s>All patients achieved complete symptom control (&gt; _90% improvement) during the first course of treatment.</s><s>Once discontinued, all patients experienced a relapse of disease, despite antihistamine treatment, within 2 to 8 weeks after their last omalizumab injection (except for 2 patients who relapsed after 4 and 7 months).</s><s>Retreatment was started at the same dose and regimen of omalizumab as the last successful treatment before discontinuation.</s><s>On the first reinjection of omalizumab, all patients responded completely and rapidly within 4 weeks but, more commonly, during the first days of retreatment.</s><s>This was the only publication to specifically investigate relapse of CIndUs and how these patients responded to omalizumab on reinitiation.</s><s>Interestingly, no patients in this study reported AEs other than mild injection-site reactions during either the initial use or during retreatment.</s></p><p><s>Variation of omalizumab use was seen between the CIndU subtypes, with the most thorough evidence available in patients with cold urticaria (complete/partial response in 41/51 patients), symptomatic dermographism (complete/partial response in 38/54 patients), and solar urticaria (complete/partial response in 28/36 patients), with the level of complete responders observed in patients with cold urticaria comparable with the efficacy reported from clinical trials with CSU. <ref type="bibr" target="#b95">94</ref></s><s>Little or no evidence was available on vibratory angioedema and aquagenic and contact urticaria, and therefore the use of omalizumab and its outcome in patients with these CIndUs should be documented and reported.</s></p><p><s>Several cases were identified of omalizumab use in children, <ref type="bibr" target="#b45">46,</ref><ref type="bibr" target="#b52">53,</ref><ref type="bibr" target="#b68">69</ref> and 1 case was identified in a pregnant woman, with no unexpected side effects and no complications or harm to the unborn child. <ref type="bibr" target="#b43">44</ref></s><s>e acknowledge that omalizumab is a costly treatment option compared with some alternative treatments.</s><s>As yet, no health economic data exist to compare its cost with the health, psychologic, and economic burden of working days lost because of CIndUs.</s></p><p><s>Other drugs that target IgE are in development, such as the IgG 1 mAbs ligelizumab and quilizumab, which should be assessed for their effects in patients with CIndU. <ref type="bibr" target="#b96">95</ref></s><s>ur review is limited by the important but unavoidable fact that results could be potentially biased because we only identified published reports based on our specific MEDLINE search criteria, and failed uses of omalizumab are a lot less likely to have been reported in the literature.</s><s>This is a relevant point but is very difficult to control for in systematic reviews of this nature.</s><s>However, we did find 2 reports of omalizumab failure in patients with CIndUs and another report in which a patient with cold urticaria had to discontinue treatment because of inadequate symptom control and AEs. <ref type="bibr" target="#b44">45</ref></s><s>This indicates that some, but probably not all, negative results have been published.</s></p><p><s>Because in many patients CIndUs are not controlled by conventional H 1 -antihistamines, an unmet need exists for further controlled randomized trials in all patients with CIndUs, with special attention paid to those in which high-quality evidence in lacking.</s><s>Additionally, further mechanistic studies are required to determine the pathophysiology of CIndUs.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>FIG 1 .</head><label>1</label><figDesc><div><p><s>FIG 1. Mast cell inflammation in patients with CIndUs.</s><s>Mast cell inflammation is the final pathway that leads to urticaria symptoms.</s><s>Free IgE binds to FcεRI receptors on mast cells, thereby facilitating their activation to release proinflammatory/pathologic mediators.</s></p></div></figDesc><graphic coords="4,91.16,65.59,406.54,140.54" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>FIG 2 .</head><label>2</label><figDesc><div><p><s>FIG 2. Responses to omalizumab treatment in patients with various CIndUs.</s><s>Cases from all 43 identified publications are included.</s><s>Two trials on cold urticaria and symptomatic dermographism were placebo controlled.</s><s>Placebo results are shown as a separate bar.</s></p></div></figDesc><graphic coords="8,90.54,230.00,407.72,200.30" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>TABLE I .</head><label>I</label><figDesc><div><p><s>Classification of urticaria subtypes</s></p></div></figDesc><table><row><cell>CIndU</cell><cell>CSU</cell></row><row><cell>Physical urticaria</cell><cell>Spontaneous appearance of itchy</cell></row><row><cell></cell><cell>wheals, angioedema, or both</cell></row><row><cell></cell><cell>&gt; _6 wk because of known or</cell></row><row><cell></cell><cell>unknown causes</cell></row><row><cell>d Vibratory angioedema</cell><cell></cell></row><row><cell>Other inducible urticaria</cell><cell></cell></row><row><cell>d Cholinergic urticaria</cell><cell></cell></row><row><cell>d Contact urticaria</cell><cell></cell></row><row><cell>d Aquagenic urticaria</cell><cell></cell></row><row><cell cols="2">*Also called urticaria factitia or dermographic urticaria.</cell></row><row><cell>Also called cold contact urticaria.</cell><cell></cell></row><row><cell>àAlso called pressure urticaria.</cell><cell></cell></row><row><cell>§Also called heat contact urticaria.</cell><cell></cell></row></table><note><p><s>d Symptomatic dermographism* d Cold urticaria d Delayed-pressure urticariaà d Solar urticaria d Heat urticaria §</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>TABLE II .</head><label>II</label><figDesc><div><p><s>Published evidence of omalizumab use in patients with various CIndUsCase series or studies with &gt; _5 patients Case reports or small case series with &lt;5 patients</s></p></div></figDesc><table><row><cell>Physical urticarias</cell><cell></cell><cell></cell></row><row><cell>Symptomatic dermographism</cell><cell>d Maurer M, et al. Omalizumab is effective in symp-</cell><cell>d Ghazanfar MN, et al. Effectiveness and safety of</cell></row><row><cell></cell><cell>tomatic dermographism-results of a randomized,</cell><cell>omalizumab in chronic spontaneous or inducible</cell></row><row><cell></cell><cell>placebo controlled trial. J Allergy Clin Immunol</cell><cell>urticaria: evaluation of 154 patients. Br J Dermatol</cell></row><row><cell></cell><cell>2017 [Epub ahead of print] 38 ; 55 patients</cell><cell>2016;175:404-6 40 ; 2 patients</cell></row><row><cell></cell><cell>d Metz M, et al. Omalizumab is an effective and</cell><cell>d Krause K, et al. Antihistamine-resistant urticaria</cell></row><row><cell></cell><cell>rapidly acting therapy in difficult-to-treat chronic</cell><cell>factitia successfully treated with anti-</cell></row><row><cell></cell><cell>urticaria: a retrospective clinical analysis. J Der-</cell><cell>immunoglobulin E therapy. Allergy 2010;65:1494-</cell></row><row><cell></cell><cell>matol Sci 2014;73:57-62 39 ; 7 patients</cell><cell>5 43 ; 1 patient</cell></row><row><cell></cell><cell></cell><cell>d Metz M, et al. Anti-immunoglobulin E treatment</cell></row><row><cell></cell><cell></cell><cell>of patients with recalcitrant physical urticaria. Int</cell></row><row><cell></cell><cell></cell><cell>Arch Allergy Immunol 2011;154:177-80 41 ; 2</cell></row><row><cell></cell><cell></cell><cell>patients</cell></row><row><cell></cell><cell></cell><cell>d Metz M, et al. Retreatment with omalizumab re-</cell></row><row><cell></cell><cell></cell><cell>sults in rapid remission in chronic spontaneous</cell></row><row><cell></cell><cell></cell><cell>and inducible urticaria. JAMA Dermatol</cell></row><row><cell></cell><cell></cell><cell>2014;150:288-90 42 ; 4 patients</cell></row><row><cell></cell><cell></cell><cell>d Vieira dos Santos R, et al. Effects of omalizumab</cell></row><row><cell></cell><cell></cell><cell>in a patient with three types of chronic urticaria.</cell></row><row><cell></cell><cell></cell><cell>Br J Dermatol 2014;170:469-71 44 ; 1 patient (with</cell></row><row><cell></cell><cell></cell><cell>coexisting symptomatic dermographism, delayed-</cell></row><row><cell></cell><cell></cell><cell>pressure urticaria, and CSU)</cell></row><row><cell>Cold urticaria</cell><cell>d Metz M, et al. Omalizumab is effective in cold</cell><cell></cell></row><row><cell></cell><cell>urticaria-results of a randomized, placebo</cell><cell></cell></row><row><cell></cell><cell>controlled trial. J Allergy Clin Immunol 2017</cell><cell></cell></row><row><cell></cell><cell>[Epub ahead of print] 37 ; 31 patients</cell><cell></cell></row><row><cell></cell><cell>d Ghazanfar MN, et al. Effectiveness and safety of</cell><cell></cell></row><row><cell></cell><cell>omalizumab in chronic spontaneous or inducible</cell><cell></cell></row><row><cell></cell><cell>urticaria: evaluation of 154 patients. Br J Dermatol</cell><cell></cell></row><row><cell></cell><cell>2016;175:404-6 40 ; 5 patients</cell><cell>Treatment of</cell></row><row><cell></cell><cell>d Kitsioulis NA, et al. Omalizumab in pediatric cold</cell><cell>severe cold contact urticaria with omalizumab:</cell></row><row><cell></cell><cell>contact urticaria: warm blanket for a cold bath?</cell><cell>case reports. Case Rep Dermatol 2012;4:275-80 45 ;</cell></row><row><cell></cell><cell>Pediatr Allergy Immunol 2016;27:752-5 46 ; 5</cell><cell>2 patients</cell></row><row><cell></cell><cell>patients</cell><cell>d Le Moing A, et al. Effective treatment of idio-</cell></row><row><cell></cell><cell>d Metz M, et al. Omalizumab is an effective and</cell><cell>pathic chronic cold urticaria with omalizumab:</cell></row><row><cell></cell><cell>rapidly acting therapy in difficult-to-treat chronic</cell><cell>report of 3 cases. J Am Acad Dermatol</cell></row><row><cell></cell><cell>urticaria: a retrospective clinical analysis. J Der-</cell><cell>2013;69:e99-101 48 ; 3 patients</cell></row><row><cell></cell><cell>matol Sci 2014;73:57-62 39 ; 6 patients</cell><cell>d Metz M, et al. Anti-immunoglobulin E treatment</cell></row><row><cell></cell><cell>d Sussman G, et al. Real-life experiences with oma-</cell><cell>of patients with recalcitrant physical urticaria. Int</cell></row><row><cell></cell><cell>lizumab for the treatment of chronic urticaria. Ann</cell><cell>Arch Allergy Immunol 2011;154:177-80 41 ; 1</cell></row><row><cell></cell><cell>Allergy Asthma Immunol 2014;112:170-4 47 ; 6</cell><cell>patient</cell></row><row><cell></cell><cell>patients</cell><cell>d Metz M, et al. Retreatment with omalizumab re-</cell></row><row><cell></cell><cell></cell><cell>sults in rapid remission in chronic spontaneous</cell></row><row><cell></cell><cell></cell><cell>and inducible urticaria. JAMA Dermatol</cell></row><row><cell></cell><cell></cell><cell>2014;150:288-90 42 ; 2 patients (including 1 patient</cell></row><row><cell></cell><cell></cell><cell>with cold urticaria and cholinergic urticaria)</cell></row><row><cell>Delayed-pressure urticaria</cell><cell>d Ghazanfar MN, et al. Effectiveness and safety of</cell><cell>d Bindslev-Jensen C, Skov PS. Efficacy of omalizu-</cell></row><row><cell></cell><cell>omalizumab in chronic spontaneous or inducible</cell><cell>mab in delayed pressure urticaria: a case report.</cell></row><row><cell></cell><cell>urticaria: evaluation of 154 patients. Br J Dermatol</cell><cell>Allergy 2010;65:138-9 51 ; 1 patient</cell></row><row><cell></cell><cell>2016;175:404-6 40 ; 5 patients</cell><cell>d Geller M. Successful treatment of occupational de-</cell></row><row><cell></cell><cell>d Metz M, et al. Omalizumab is an effective and</cell><cell>layed pressure urticaria and angioedema with</cell></row><row><cell></cell><cell>rapidly acting therapy in difficult-to-treat chronic</cell><cell>omalizumab. Ann Allergy Asthma Immunol</cell></row><row><cell></cell><cell>urticaria: a retrospective clinical analysis. J Der-</cell><cell>2016;116:81-2 54 ; 1 patient</cell></row><row><cell></cell><cell>matol Sci 2014;73:57-62 39 ; 8 patients</cell><cell>d Kasperska-Zajac A, et al. Effective treatment of</cell></row><row><cell></cell><cell></cell><cell>different phenotypes of chronic urticaria with</cell></row><row><cell></cell><cell></cell><cell>omalizumab: case reports and review of literature.</cell></row><row><cell></cell><cell></cell><cell>Int J Immunopathol Pharmacol 2016;29:320-8 56 ; 3</cell></row><row><cell></cell><cell></cell><cell>patients (all with coexisting CSU)</cell></row></table><note><p><s>d Alba Mar ın JC, et al.</s><s>Treatment of severe coldinduced urticaria in a child with omalizumab.</s><s>J Investig Allergol Clin Immunol 2015;25:303-4 49 ; 1 patient d Boyce JA.</s><s>Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE.</s><s>J Allergy Clin Immunol 2006;117:1415-8 19 ; 1 patient d Brodsk a P, Schmid-Grendelmeier P. d Metz M, et al.</s><s>Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria.</s><s>Int Arch Allergy Immunol 2011;154:177-80 41 ; 1 patient (Continued)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>TABLE II .</head><label>II</label><figDesc><div><p><s>(Continued)</s></p></div></figDesc><table><row><cell>Case series or studies with &gt; _5 patients</cell><cell cols="2">Case reports or small case series with &lt;5 patients</cell></row><row><cell></cell><cell cols="2">d Metz M, et al. Retreatment with omalizumab re-</cell></row><row><cell></cell><cell cols="2">sults in rapid remission in chronic spontaneous</cell></row><row><cell></cell><cell cols="2">and inducible urticaria. JAMA Dermatol</cell></row><row><cell></cell><cell cols="2">2014;150:288-90 42 ; 6 patients (5 with delayed-</cell></row><row><cell></cell><cell cols="2">pressure urticaria and CSU)</cell></row><row><cell></cell><cell cols="2">d M€ uller S, et al. Bullous delayed pressure urticaria</cell></row><row><cell></cell><cell cols="2">responding to omalizumab. Acta Derm Venereol</cell></row><row><cell></cell><cell cols="2">2016;96:416-7 50 ; 1 patient</cell></row><row><cell></cell><cell cols="2">d Quintero OP, et al. Rapid response to omalizumab</cell></row><row><cell></cell><cell cols="2">in 3 cases of delayed pressure urticaria. J Allergy</cell></row><row><cell></cell><cell cols="2">Clin Immunol Pract 2017;5:179-80 52 ; 3 patients</cell></row><row><cell></cell><cell cols="2">d Rodr ıguez-Rodr ıguez M, et al. Successful treat-</cell></row><row><cell></cell><cell cols="2">ment of severe delayed pressure angio-oedema</cell></row><row><cell></cell><cell cols="2">with omalizumab. Allergol Immunopathol (Madr)</cell></row><row><cell></cell><cell cols="2">2014;42:78-80 55 ; 1 patient</cell></row><row><cell></cell><cell cols="2">d Netchiporouk E, et al. Management of pediatric</cell></row><row><cell></cell><cell cols="2">chronic spontaneous and physical urticaria pa-</cell></row><row><cell></cell><cell cols="2">tients with Omalizumab: case series. Pediatr Al-</cell></row><row><cell></cell><cell cols="2">lergy Immunol 2015;26:585-8 53 ; 1 patient (with</cell></row><row><cell></cell><cell cols="2">delayed-pressure urticaria and CSU)</cell></row><row><cell></cell><cell cols="2">d Vieira dos Santos R, et al. Effects of omalizumab</cell></row><row><cell></cell><cell cols="2">in a patient with three types of chronic urticaria.</cell></row><row><cell></cell><cell cols="2">Br J Dermatol 2014;170:469-71 44 ; 1 patient (with</cell></row><row><cell></cell><cell cols="2">coexisting delayed-pressure urticaria, symptomatic</cell></row><row><cell></cell><cell cols="2">dermographism, and CSU)</cell></row><row><cell>Solar urticaria</cell><cell></cell></row><row><cell></cell><cell></cell><cell>583-</cell></row><row><cell></cell><cell>5 61 ; 1 patient</cell></row><row><cell></cell><cell cols="2">d Baliu-Piqu e C, Aguilera Peir o P. Three cases of so-</cell></row><row><cell></cell><cell cols="2">lar urticaria successfully treated with omalizumab.</cell></row><row><cell></cell><cell cols="2">J Eur Acad Dermatol Venereol 2016;30:704-6 62 ; 3</cell></row><row><cell></cell><cell>patients</cell></row><row><cell></cell><cell cols="2">d Br€ uning JH, et al. Successful treatment of solar ur-</cell></row><row><cell></cell><cell cols="2">ticaria with omalizumab. J Dtsch Dermatol Ges</cell></row><row><cell></cell><cell cols="2">2016;14:936-7 68 ; 1 patient</cell></row><row><cell></cell><cell cols="2">d Combalia A, et al. Refractory solar urticaria suc-</cell></row><row><cell></cell><cell cols="2">cessfully treated with omalizumab with normali-</cell></row><row><cell></cell><cell cols="2">zation of phototest. Actas Dermosifiliogr</cell></row><row><cell></cell><cell cols="2">2017;108:593-4 63 ; 1 patient</cell></row><row><cell></cell><cell>d de Dios-Vel azquez</cell><cell>A, et al. Effectiveness of oma-</cell></row><row><cell></cell><cell cols="2">lizumab in severe solar urticaria. Ann Allergy</cell></row><row><cell></cell><cell cols="2">Asthma Immunol 2016;116:260 64 ; 1 patient</cell></row><row><cell></cell><cell cols="2">d Duchini G, et al. Failure of omalizumab (XolairÒ)</cell></row><row><cell></cell><cell cols="2">in the treatment of a case of solar urticaria caused</cell></row><row><cell></cell><cell cols="2">by ultraviolet A and visible light. Photodermatol</cell></row><row><cell></cell><cell cols="2">Photoimmunol Photomed 2011;27:336-7 59 ; 1</cell></row><row><cell></cell><cell>patient</cell></row><row><cell></cell><cell cols="2">d Ghazanfar MN, et al. Effectiveness and safety of</cell></row><row><cell></cell><cell cols="2">omalizumab in chronic spontaneous or inducible</cell></row><row><cell></cell><cell cols="2">urticaria: evaluation of 154 patients. Br J Dermatol</cell></row><row><cell></cell><cell cols="2">2016;175:404-6 40 ; 1 patient</cell></row><row><cell></cell><cell cols="2">d Guzelbey O, et al. Successful treatment of solar ur-</cell></row><row><cell></cell><cell cols="2">ticaria with anti-immunoglobulin E therapy. Al-</cell></row><row><cell></cell><cell cols="2">lergy 2008;63:1563-5 65 ; 1 patient</cell></row><row><cell></cell><cell cols="2">d Kowalzick L, et al. Partial response of solar urti-</cell></row><row><cell></cell><cell cols="2">caria to omalizumab therapy. Hautarzt</cell></row><row><cell></cell><cell cols="2">2017;68:492-6 57 ; 1 patient</cell></row></table><note><p><s>d Aubin F, et al.</s><s>Omalizumab in patients with severe and refractory solar urticaria: a phase II multicentric study.</s><s>J Am Acad Dermatol 2016;74:574-5 36 ; 10 patients d Arasi S, et al.</s><s>Treatment with omalizumab in a 16year-old Caucasian girl with refractory solar urticaria.</s><s>Pediatr Allergy Immunol 2015;26:d Levi A, et al.</s><s>Successful omalizumab treatment of severe solar urticaria in a 6-year-old child.</s><s>Pediatr Allergy Immunol 2015;26:588-90 69 ; 1 patient (Continued)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>TABLE II .</head><label>II</label><figDesc><div><p><s>(Continued)</s></p></div></figDesc><table><row><cell></cell><cell>Case series or studies with &gt; _5 patients</cell><cell>Case reports or small case series with &lt;5 patients</cell></row><row><cell></cell><cell></cell><cell>d Metz M, et al. Anti-immunoglobulin E treatment</cell></row><row><cell></cell><cell></cell><cell>of patients with recalcitrant physical urticaria. Int</cell></row><row><cell></cell><cell></cell><cell>Arch Allergy Immunol 2011;154:177-80 41 ; 2</cell></row><row><cell></cell><cell></cell><cell>patients</cell></row><row><cell></cell><cell></cell><cell>d Metz M, et al. Retreatment with omalizumab re-</cell></row><row><cell></cell><cell></cell><cell>sults in rapid remission in chronic spontaneous</cell></row><row><cell></cell><cell></cell><cell>and inducible urticaria. JAMA Dermatol</cell></row><row><cell></cell><cell></cell><cell>2014;150:288-90 42 ; 1 patient</cell></row><row><cell></cell><cell></cell><cell>d Metz M, et al. Omalizumab is an effective and</cell></row><row><cell></cell><cell></cell><cell>rapidly acting therapy in difficult-to-treat chronic</cell></row><row><cell></cell><cell></cell><cell>urticaria: a retrospective clinical analysis. J Der-</cell></row><row><cell></cell><cell></cell><cell>matol Sci 2014;73:57-62 39 ; 4 patients</cell></row><row><cell></cell><cell></cell><cell>d Moncourier M, et al. Visible light-induced solar</cell></row><row><cell></cell><cell></cell><cell>urticaria is improved by omalizumab. Photoder-</cell></row><row><cell></cell><cell></cell><cell>matol Photoimmunol Photomed 2016;32:314-6 66 ;</cell></row><row><cell></cell><cell></cell><cell>4 patients</cell></row><row><cell></cell><cell></cell><cell>d M€ uller S, et al. Failure of omalizumab in the treat-</cell></row><row><cell></cell><cell></cell><cell>ment of solar urticaria. J Eur Acad Dermatol Ve-</cell></row><row><cell></cell><cell></cell><cell>nereol 2016;30:524-5 60 ; 1 patient</cell></row><row><cell></cell><cell></cell><cell>d Terrani I, et al. Solar urticaria induced by visible</cell></row><row><cell></cell><cell></cell><cell>light: successful treatment with omalizumab. Clin</cell></row><row><cell></cell><cell></cell><cell>Exp Dermatol 2016;41:890-2 67 ; 1 patient</cell></row><row><cell></cell><cell></cell><cell>d Waibel KH, et al. Partial improvement of solar ur-</cell></row><row><cell></cell><cell></cell><cell>ticaria after omalizumab. J Allergy Clin Immunol</cell></row><row><cell></cell><cell></cell><cell>2010;125:490-1 58 ; 1 patient</cell></row><row><cell>Heat urticaria</cell><cell>NA</cell><cell>d Bullerkotte U, et al. Effective treatment of refrac-</cell></row><row><cell></cell><cell></cell><cell>tory severe heat urticaria with omalizumab. Al-</cell></row><row><cell></cell><cell></cell><cell>lergy 2010;65:931-2 20 ; 1 patient</cell></row><row><cell></cell><cell></cell><cell>d Carballada F, et al. Omalizumab treatment in 2</cell></row><row><cell></cell><cell></cell><cell>cases of refractory heat urticaria. J Investig Aller-</cell></row><row><cell></cell><cell></cell><cell>gol Clin Immunol 2013;23:519-21 70 ; 2 patients</cell></row><row><cell></cell><cell></cell><cell>d Metz M, et al. Anti-immunoglobulin E treatment</cell></row><row><cell></cell><cell></cell><cell>of patients with recalcitrant physical urticaria. Int</cell></row><row><cell></cell><cell></cell><cell>Arch Allergy Immunol 2011;154:177-80 41 ; 1</cell></row><row><cell></cell><cell></cell><cell>patient</cell></row><row><cell></cell><cell></cell><cell>d Metz M, et al. Omalizumab is an effective and</cell></row><row><cell></cell><cell></cell><cell>rapidly acting therapy in difficult-to-treat chronic</cell></row><row><cell></cell><cell></cell><cell>urticaria: a retrospective clinical analysis. J Der-</cell></row><row><cell></cell><cell></cell><cell>matol Sci 2014;73:57-62 39 ; 1 patient</cell></row><row><cell>Vibratory angioedema</cell><cell>NA</cell><cell>d Pressler A, et al. Failure of omalizumab and suc-</cell></row><row><cell></cell><cell></cell><cell>cessful control with ketotifen in a patient with</cell></row><row><cell></cell><cell></cell><cell>vibratory angio-oedema. Clin Exp Dermatol</cell></row><row><cell></cell><cell></cell><cell>2013;38:151-3 71 ; 1 patient</cell></row><row><cell>Other inducible urticarias</cell><cell></cell><cell></cell></row><row><cell>Cholinergic urticaria</cell><cell>d Metz M, et al. Omalizumab is an effective and</cell><cell>d Ghazanfar MN, et al. Effectiveness and safety of</cell></row><row><cell></cell><cell>rapidly acting therapy in difficult-to-treat chronic</cell><cell>omalizumab in chronic spontaneous or inducible</cell></row><row><cell></cell><cell>urticaria: a retrospective clinical analysis. J</cell><cell>urticaria: evaluation of 154 patients. Br J Dermatol</cell></row><row><cell></cell><cell>Dermatol Sci 2014;73:57-62 39 ; 8 patients</cell><cell>2016;175:404-6 40 ; 4 patients</cell></row><row><cell></cell><cell></cell><cell>d Kutlu A, et al. Healing effects of omalizumab in a</cell></row><row><cell></cell><cell></cell><cell>patient with cholinergic urticaria associated severe</cell></row><row><cell></cell><cell></cell><cell>dyspeptic complaints. Chin Med J (Engl)</cell></row><row><cell></cell><cell></cell><cell>2015;128:1559-60 75 ; 1 patient</cell></row><row><cell></cell><cell></cell><cell>d Metz M, et al. Retreatment with omalizumab re-</cell></row><row><cell></cell><cell></cell><cell>sults in rapid remission in chronic spontaneous</cell></row><row><cell></cell><cell></cell><cell>and inducible urticaria. JAMA Dermatol</cell></row><row><cell></cell><cell></cell><cell>2014;150:288-90 42 ; 4 patients (including 1 patient</cell></row><row><cell></cell><cell></cell><cell>with cholinergic urticaria and cold urticaria)</cell></row></table><note><p><s>d Metz M, et al.</s><s>Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy.</s><s>Allergy 2008;63:247-9 72 ; 1 patient d Otto HF, Calabria CW.</s><s>A case of severe refractory chronic urticaria: a novel method for evaluation (Continued)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>TABLE II .</head><label>II</label><figDesc><div><p><s>(Continued) Case series or studies with &gt; _5 patients Case reports or small case series with &lt;5 patients and treatment.</s><s>Allergy Asthma Proc 2009;30:333-7 73 ; 1 patient d Sabroe RA.</s><s>Failure of omalizumab in cholinergic urticaria.</s><s>Clin Exp Dermatol 2010;35:e127-9 74 ; 1 patient</s></p></div></figDesc><table><row><cell>Contact urticaria</cell><cell>NA</cell><cell>NA</cell></row><row><cell>Aquagenic urticaria</cell><cell>NA</cell><cell></cell></row></table><note><p><s>d Rorie A, Gierer S. A case of aquagenic urticaria successfully treated with omalizumab.</s><s>J Allergy Clin Immunol Pract 2016;4:547-8 76 ; 1 patient</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 2</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J ALLERGY CLIN IMMUNOLFEBRUARY 2018</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>We thank Gillian Brodie for editorial help with the preparation of this review.</s><s>Gillian's help was made possible by the support of the Urticaria Network e.V. (www.urtikaria.net),</s><s>which we gratefully acknowledge.</s></p><p><s>Clinical implications: Substantial evidence of omalizumab efficacy exists in patients with CIndUs.</s><s>It has shown significant benefits in therapy-refractory patients and can provide a much needed option when antihistamine treatment has failed.</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The EAACI/GA 2 LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Aberer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Asero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Brzoza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Canonica</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="868" to="887" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Prevalence of inducible urticaria in patients with chronic spontaneous urticaria: associated risk factors</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sanchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Amaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Acevedo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Celis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Caraballo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cardona</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol Pract</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="464" to="470" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria</title>
		<author>
			<persName><forename type="first">M</forename><surname>S Anchez-Borges</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Caballero-Fonseca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Capriles-Hulett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gonz Alez-Aveledo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="964" to="971" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">The definition, diagnostic testing, and management of chronic inducible urticarias-the EAACI/GA 2 LEN/EDF/UNEV consensus recommendations 2016 update and revision</title>
		<author>
			<persName><forename type="first">M</forename><surname>Magerl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Altrichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Borzova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gimenez-Arnau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Grattan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lawlor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="780" to="802" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Effect of chronic urticaria on US patients: analysis of the National Health and Wellness Survey</title>
		<author>
			<persName><forename type="first">J</forename><surname>Vietri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Turner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Isherwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Balp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gabriel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Allergy Asthma Immunol</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="306" to="311" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Quality of life in patients with urticaria and angioedema: assessing burden of disease</title>
		<author>
			<persName><forename type="first">D</forename><surname>Weldon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy Asthma Proc</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="4" to="9" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria</title>
		<author>
			<persName><forename type="first">K</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Werner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Altrichter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page" from="1483" to="1485" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>e9</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Rupatadine 20 mg and 40 mg are effective in reducing the symptoms of chronic cold urticaria</title>
		<author>
			<persName><forename type="first">M</forename><surname>Abajian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Curto-Barredo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Santamaria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Izquierdo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Church</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Derm Venereol</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="56" to="59" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Omalizumab for the treatment of chronic urticaria</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Rev Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="171" to="180" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Hsieh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Saini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Grattan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gimenez-Arnau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="page" from="924" to="935" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ledford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ashby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Canvin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Zazzali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Conner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="101" to="109" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria</title>
		<author>
			<persName><forename type="first">S</forename><surname>Saini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Hsieh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Conner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kaplan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="567" to="573" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>e1</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Saini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Grob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bulbul</forename><surname>Baskan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bradley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page">925</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial</title>
		<author>
			<persName><forename type="first">P</forename><surname>Staubach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Chapman-Rothe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sieder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Brautigam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Canvin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="1135" to="1144" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Altrichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Bieber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Biedermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Brautigam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Seyfried</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="202" to="209" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>e5</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin</title>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Staubach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Brehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gericke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kangas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Theranostics</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="1266" to="1276" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Omalizumab-an effective and safe treatment of therapy-resistant chronic spontaneous urticaria</title>
		<author>
			<persName><forename type="first">A</forename><surname>Groffik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Mitzel-Kaoukhov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Magerl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Staubach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="303" to="305" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">T</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Ji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Meng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hawro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Wei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="1742" to="1750" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>e4</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Boyce</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="1415" to="1418" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Effective treatment of refractory severe heat urticaria with omalizumab</title>
		<author>
			<persName><forename type="first">U</forename><surname>Bullerkotte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wieczorek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kapp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wedi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="931" to="932" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Omalizumab is effective in nonautoimmune urticaria</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ferrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gamboa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Sanz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Goikoetxea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cabrera-Freitag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Javaloyes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="1300" to="1302" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Effects of omalizumab treatment in patients with refractory chronic urticaria</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Nam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Ye</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy Asthma Immunol Res</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="357" to="361" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Church</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="337" to="342" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Assessment of tissue fluid histamine levels in patients with urticaria</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Horakova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Katz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="350" to="354" />
			<date type="published" when="1978">1978</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Chronic idiopathic urticaria: profiles of skin mast cell histamine release during active disease and remission</title>
		<author>
			<persName><forename type="first">P</forename><surname>Jacques</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lavoie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Bedard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Brunet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hebert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="1139" to="1143" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Autoimmune chronic spontaneous urticaria: what we know and what we don&apos;t know</title>
		<author>
			<persName><forename type="first">P</forename><surname>Kolkhir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Church</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Schmetzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="1772" to="1781" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>e1</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction</title>
		<author>
			<persName><forename type="first">Kring</forename><surname>Tannert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Stahl</forename><surname>Skov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Bjerremann</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatology</title>
		<imprint>
			<biblScope unit="volume">224</biblScope>
			<biblScope unit="page" from="101" to="105" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">IgE mediated autoallergy against thyroid peroxidase-a novel pathomechanism of chronic spontaneous urticaria?</title>
		<author>
			<persName><forename type="first">S</forename><surname>Altrichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Peter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pisarevskaja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Martus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">e14794</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Histamine release-neutralization assay for sera of patients with atopic dermatitis and/or cholinergic urticaria is useful to screen type I hypersensitivity against sweat antigens</title>
		<author>
			<persName><forename type="first">H</forename><surname>Shindo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ishii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yanase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hide</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol Res</title>
		<imprint>
			<biblScope unit="volume">304</biblScope>
			<biblScope unit="page" from="647" to="654" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Symptomatic dermographism (factitious urticaria)-passive transfer experiments from human to monkey</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Zollman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Greaves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Winkelmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="801" to="804" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Dermographia mediated by immunoglobulin E</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Newcomb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nelson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="174" to="180" />
			<date type="published" when="1973">1973</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Idiopathic cold urticaria: in vitro demonstration of histamine release upon challenge of skin biopsies</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Garofalo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sigler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hauber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">305</biblScope>
			<biblScope unit="page" from="1074" to="1077" />
			<date type="published" when="1981">1981</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Gruber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Baeza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Marchese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Agnello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Kaplan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="213" to="217" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Allergic hypersensitivity skin reactions following sun exposure</title>
		<author>
			<persName><forename type="first">Lugovic</forename><surname>Mihic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bulat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Situm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cavka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Krolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Coll Antropol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="153" to="157" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma</title>
		<author>
			<persName><forename type="first">G</forename><surname>Hochhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Brookman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Matthews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Med Res Opin</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="491" to="498" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Omalizumab in patients with severe and refractory solar urticaria: A phase II multicentric study</title>
		<author>
			<persName><forename type="first">F</forename><surname>Aubin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Avenel-Audran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jeanmougin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Adamski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Peyron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Marguery</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="574" to="575" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Omalizumab is effective in cold urticaria-results of a randomized, placebo controlled trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sch€ Utz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gorczyza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zimmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Staubach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>Epub ahead of print</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Omalizumab is effective in symptomatic dermographism-results of a randomized, placebo controlled trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sch€ Utz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Schoepke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Peveling-Oberhag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Staubach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>Epub ahead of print</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ohanyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Church</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Dermatol Sci</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="57" to="62" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Ghazanfar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Thomsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">175</biblScope>
			<biblScope unit="page" from="404" to="406" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Antiimmunoglobulin E treatment of patients with recalcitrant physical urticaria</title>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Altrichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ardelean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kessler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Magerl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Arch Allergy Immunol</title>
		<imprint>
			<biblScope unit="volume">154</biblScope>
			<biblScope unit="page" from="177" to="180" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria</title>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ohanyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Church</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Dermatol</title>
		<imprint>
			<biblScope unit="volume">150</biblScope>
			<biblScope unit="page" from="288" to="290" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Antihistamine-resistant urticaria factitia successfully treated with antiimmunoglobulin E therapy</title>
		<author>
			<persName><forename type="first">K</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ardelean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kessler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Magerl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Siebenhaar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="1494" to="1495" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Effects of omalizumab in a patient with three types of chronic urticaria</title>
		<author>
			<persName><forename type="first">R</forename><surname>Vieira Dos Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Locks</forename><surname>Bidese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Rabello</forename><surname>De Souza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">170</biblScope>
			<biblScope unit="page" from="469" to="471" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Treatment of severe cold contact urticaria with omalizumab: case reports</title>
		<author>
			<persName><forename type="first">P</forename><surname>Brodska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Schmid-Grendelmeier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Case Rep Dermatol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="275" to="280" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Omalizumab in pediatric cold contact urticaria: warm blanket for a cold bath</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Kitsioulis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Xepapadaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kostoudi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Manousakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Douladiris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Papadopoulos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Allergy Immunol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="752" to="755" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Real-life experiences with omalizumab for the treatment of chronic urticaria</title>
		<author>
			<persName><forename type="first">G</forename><surname>Sussman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Barron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Caron-Guay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Laflamme</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Allergy Asthma Immunol</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="170" to="174" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Effective treatment of idiopathic chronic cold urticaria with omalizumab: report of 3 cases</title>
		<author>
			<persName><forename type="first">Le</forename><surname>Moing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Becourt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pape</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Dejobert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Delaporte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Staumont-Salle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="e99" to="101" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Treatment of severe cold-induced urticaria in a child with omalizumab</title>
		<author>
			<persName><forename type="first">Alba</forename><surname>Marin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Martorell</forename><surname>Aragones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Satorre</forename><surname>Viejo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Gastaldo</forename><surname>Simeon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Investig Allergol Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="303" to="304" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Bullous delayed pressure urticaria responding to omalizumab</title>
		<author>
			<persName><forename type="first">S</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rafei-Shamsabadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Technau-Hafsi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Renzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jakob</forename><forename type="middle">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Derm Venereol</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="416" to="417" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Efficacy of omalizumab in delayed pressure urticaria: a case report</title>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Skov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="138" to="139" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Rapid response to omalizumab in 3 cases of delayed pressure urticaria</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">P</forename><surname>Quintero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Arrondo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Veleiro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol Pract</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="179" to="180" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series</title>
		<author>
			<persName><forename type="first">E</forename><surname>Netchiporouk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Thuraisingham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Jafarian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ben-Shoshan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Allergy Immunol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="585" to="588" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Successful treatment of occupational delayed pressure urticaria and angioedema with omalizumab</title>
		<author>
			<persName><forename type="first">M</forename><surname>Geller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Allergy Asthma Immunol</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="81" to="82" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Successful treatment of severe delayed pressure angio-oedema with omalizumab</title>
		<author>
			<persName><forename type="first">M</forename><surname>Rodriguez-Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Antolin-Amerigo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Barbarroja-Escudero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Sanchez-Gonzalez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Alvarez-Mon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergol Immunopathol (Madr)</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="78" to="80" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Effective treatment of different phenotypes of chronic urticaria with omalizumab: case reports and review of literature</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kasperska-Zajac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jarzab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zerdzinska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Grzanka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Immunopathol Pharmacol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="320" to="328" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">L</forename><surname>Kowalzick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Thiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bielfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ziegler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Eickenscheidt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hautarzt</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="492" to="496" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>Partial response of solar urticaria to omalizumab therapy</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Partial improvement of solar urticaria after omalizumab</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Waibel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Reese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Hamilton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Devillez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="490" to="491" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Failure of omalizumab (Xolair(R)) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light</title>
		<author>
			<persName><forename type="first">G</forename><surname>Duchini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Baumler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Bircher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Scherer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Photodermatol Photoimmunol Photomed</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="336" to="337" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Failure of omalizumab in the treatment of solar urticaria</title>
		<author>
			<persName><forename type="first">S</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Schempp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Jakob</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="524" to="525" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Treatment with omalizumab in a 16-year-old Caucasian girl with refractory solar urticaria</title>
		<author>
			<persName><forename type="first">S</forename><surname>Arasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Crisafulli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Caminiti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Guarneri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Aversa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Porcaro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Allergy Immunol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="583" to="585" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Three cases of solar urticaria successfully treated with omalizumab</title>
		<author>
			<persName><forename type="first">C</forename><surname>Baliu-Pique</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aguilera</forename><surname>Peiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="704" to="706" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Refractory solar urticaria successfully treated with omalizumab with normalization of phototest</title>
		<author>
			<persName><forename type="first">A</forename><surname>Combalia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fernandez-Sartorio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Aguilera</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Actas Dermosifiliogr</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="593" to="594" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Effectiveness of omalizumab in severe solar urticaria</title>
		<author>
			<persName><forename type="first">A</forename><surname>De Dios-Velazquez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gonzalez-De Arriba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Beteta-Gorriti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Macias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Campanon-Toro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Davila</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Allergy Asthma Immunol</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="260" to="262" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Successful treatment of solar urticaria with anti-immunoglobulin E therapy</title>
		<author>
			<persName><forename type="first">O</forename><surname>Guzelbey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ardelean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Magerl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="1563" to="1565" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Visible light-induced solar urticaria is improved by omalizumab</title>
		<author>
			<persName><forename type="first">M</forename><surname>Moncourier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Assikar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Matei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Souyri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Couture</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Rigot</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Photodermatol Photoimmunol Photomed</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="314" to="316" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Solar urticaria induced by visible light: successful treatment with omalizumab</title>
		<author>
			<persName><forename type="first">I</forename><surname>Terrani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Bircher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Scherer</forename><surname>Hofmeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="890" to="892" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Successful treatment of solar urticaria with omalizumab</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Bruning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ziemer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pemler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Treudler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Dtsch Dermatol Ges</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="936" to="937" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Successful omalizumab treatment of severe solar urticaria in a 6-year-old child</title>
		<author>
			<persName><forename type="first">A</forename><surname>Levi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Dranitzki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shalit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Enk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Allergy Immunol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="588" to="590" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Omalizumab treatment in 2 cases of refractory heat urticaria</title>
		<author>
			<persName><forename type="first">F</forename><surname>Carballada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nunez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Martin-Lazaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Juarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Castineira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Carballada</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Investig Allergol Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="519" to="521" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema</title>
		<author>
			<persName><forename type="first">A</forename><surname>Pressler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Grosber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Halle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Brockow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="151" to="153" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy</title>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bergmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="247" to="249" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">A case of severe refractory chronic urticaria: a novel method for evaluation and treatment</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Otto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Calabria</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy Asthma Proc</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="333" to="337" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Failure of omalizumab in cholinergic urticaria</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Sabroe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="e127" to="129" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Healing effects of omalizumab in a patient with cholinergic urticaria associated severe dyspeptic complaints</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kutlu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tanoglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ozturk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chin Med J (Engl)</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="1559" to="1560" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">A case of aquagenic urticaria successfully treated with omalizumab</title>
		<author>
			<persName><forename type="first">A</forename><surname>Rorie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gierer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol Pract</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="547" to="548" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Acquired cold urticaria: clinical picture and update on diagnosis and treatment</title>
		<author>
			<persName><forename type="first">F</forename><surname>Siebenhaar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mlynek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Magerl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Altrichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vieira Dos Santos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="241" to="245" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Physical urticaria: classification and diagnostic guidelines. An EAACI position paper</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kontou-Fili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Borici-Mazi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kapp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Matjevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">B</forename><surname>Mitchel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="504" to="513" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Urticarial dermographism: clinical features and response to psychosocial stress</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wallengren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Isaksson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Derm Venereol</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="493" to="498" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Symptomatic dermographism: an inadequately described disease</title>
		<author>
			<persName><forename type="first">N</forename><surname>Schoepke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mlynek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Church</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="708" to="712" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Kounis following cold urticaria: the swimmer&apos;s death</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mazarakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bardousis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Almpanis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Mazaraki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Markou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Kounis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">176</biblScope>
			<biblScope unit="page" from="e52" to="53" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">K</forename><surname>Brandes</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Cold urticaria and swimmer&apos;s death</note>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Z Allgemeinmed</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="1219" to="1220" />
			<date type="published" when="1970">1970</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">P</forename><surname>Delore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gerin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chapuy</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J Med Lyon</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="497" to="503" />
			<date type="published" when="1956">1956</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Essential cold urticaria. A potential cause of death while swimming</title>
		<author>
			<persName><forename type="first">C</forename><surname>Sigal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Mitchell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Can Med Assoc J</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="609" to="610" />
			<date type="published" when="1964">1964</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Diagnosis and incidence of delayed pressure urticaria in patients with chronic urticaria</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Barlow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Warburton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Watson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Black</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Greaves</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="954" to="958" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Kobza-Black A. The extent and nature of disability in different urticarial conditions</title>
		<author>
			<persName><forename type="first">E</forename><surname>Poon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>Seed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Greaves</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">140</biblScope>
			<biblScope unit="page" from="667" to="671" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Solar urticaria</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Botto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Warshaw</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="909" to="922" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<monogr>
		<title level="m" type="main">Solar urticaria patient information leaflet</title>
		<ptr target="http://www.bad.org.uk/shared/get-file.ashx?id=129&amp;itemtype=document" />
		<imprint>
			<date type="published" when="2016-08-14">2016. August 14, 2017</date>
		</imprint>
	</monogr>
	<note>British Association of Dermatologists</note>
</biblStruct>

<biblStruct xml:id="b90">
	<monogr>
		<title level="m" type="main">Fitzpatrick&apos;s Dermatology</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fluhr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Amagai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bruckner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Enk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Margolis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mcmichael</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Orringer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kang</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2017">2017</date>
			<pubPlace>New York</pubPlace>
		</imprint>
	</monogr>
	<note>Solar urticaria. 9th ed</note>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">EAACI/GA 2 LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Asero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Walter</forename><surname>Canonica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Church</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Gimenez-Arnau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="1417" to="1426" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Urticaria: current opinions about etiology, diagnosis and therapy</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Derm Venereol</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="196" to="205" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Immediate contact skin reactions, an update of contact urticaria, contact urticaria syndrome and protein contact dermatitis-&apos;&apos;a never ending story</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gimenez-Arnau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>De La Cuadra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Maibach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Dermatol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="552" to="562" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria</title>
		<author>
			<persName><forename type="first">J</forename><surname>Gericke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ohanyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Altrichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Skov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="1059" to="1061" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>e1</note>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Similar efficacy with omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Casale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Bernstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Saini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Trzaskoma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol Pract</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="743" to="750" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>e1</note>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Cabanski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Scheerens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Samineni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Bradley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cochran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page" from="1730" to="1732" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
